Therapies for rare diseases: therapeutic modalities, progress and challenges ahead

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1

Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139

Continuous cultures of fused cells secreting antibody of predefined specificity

Köhler, G., & Milstein, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,200

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,484

Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework

Biomarkers Definitions Working Group (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,771

Drug repurposing: progress, challenges and recommendations

Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.019 · Cited by 3,720

Update on Key Emerging Challenges in Cystic Fibrosis

Jennings, M. T., Riekert, K. A., & Boyle, M. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,671

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047

Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries

Jostock, T., Vanhove, M., Brepoels, E., van Gool, R., Daukandt, M., Wehnert, A., van Hegelsom, R., Dransfield, D., Sexton, D., Devlin, M., et al. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.03.014 · Cited by 2,572

Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension

Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D. B., Fleming, T. R., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,466

Gene-editing technology, from macromolecule therapeutics to organ transplantation: Applications, limitations, and prospective uses

Harisa, G. I., Faris, T. M., Sherif, A. Y., Alzhrani, R. F., Alanazi, S. A., Kohaf, N. A., & Alanazi, F. K. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127055 · Cited by 17

Rare Disease Policy in High-Income Countries: An Overview of Achievements, Challenges, and Solutions

Gentilini, A., Neez, E., & Wong‐Rieger, D. (2025) · Value in Health · doi:10.1016/j.jval.2024.12.009 · Cited by 17

NANOSPRESSO: toward personalized, locally produced nucleic acid nanomedicines

Sentí, M. E., Ceccaldi, A., Luciani, M., Saber, N., Schürmann, P. J. L., Geerlings, M. W., Hölig, P., de Beer, J., Hannus, M., Campbell, F., et al. (2025) · Frontiers in Science · doi:10.3389/fsci.2025.1458636 · Cited by 17

Kidney Cancer and Chronic Kidney Disease: Too Close for Comfort

Caetano-Pinto, P., Rönnau, C., Burchardt, M., & Wolff, I. (2021) · Biomedicines · doi:10.3390/biomedicines9121761 · Cited by 17

RNA-based therapies for neurodegenerative disease: Targeting molecular mechanisms for disease modification

Bhati, V., Prasad, S., & Kabra, A. (2025) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2025.104010 · Cited by 19

Gnas Loss Causes Chondrocyte Fate Conversion in Cranial Suture Formation

Xu, R., Liu, Y., Zhou, Y. L., Lin, W., Yuan, Q., Zhou, X., & Yang, Y. (2022) · Journal of Dental Research · doi:10.1177/00220345221075215 · Cited by 15

Enhanced metabolism and negative regulation of ER stress support higher erythropoietin production in HEK293 cells

Saghaleyni, R., Malm, M., Moruzzi, N., Zrimec, J., Razavi, R., Wistbacka, N., Thorell, H., Pintar, A., Hober, A., Edfors, F., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110936 · Cited by 15

Emergent treatments for β-thalassemia and orphan drug legislations

Costa, E., Cappellini, M. D., Rivella, S., Chilin, A., Alessi, E., Riccaboni, M., Leufkens, H. G. M., & Luzzatto, L. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103342 · Cited by 14

Curcumin Has Beneficial Effects on Lysosomal Alpha-Galactosidase: Potential Implications for the Cure of Fabry Disease

Monticelli, M., Mele, B. H., Allocca, M., Liguori, L., Lukáš, J., Monti, M. C., Morretta, E., Cubellis, M. V., & Andreotti, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021095 · Cited by 15

Getting the Dose Right in Drug Development for Rare Diseases: Barriers and Enablers

AHMED, M. A., Krishna, R., Rayad, N., Albusaysi, S., Mitra, A., Shang, E. Y., Hon, Y. Y., Abuasal, B., Bakhaidar, R. B., Roman, Y. M., et al. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3407 · Cited by 15

Using Bibliometric Analysis and Machine Learning to Identify Compounds Binding to Sialidase-1

Klein, J. J., Baker, N., Foil, D. H., Zorn, K. M., Urbina, F., Puhl, A. C., & Ekins, S. (2021) · ACS Omega · doi:10.1021/acsomega.0c05591 · Cited by 15

The frequency of rare and monogenic diseases in pediatric organ transplant recipients in Italy

Vaisitti, T., Peritore, D., Magistroni, P., Ricci, A., Lombardini, L., Gringeri, E., Catalano, S., Spada, M., Sciveres, M., Giorgio, A. D., et al. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-02013-x · Cited by 15

Glaucoma in mucopolysaccharidoses

Kong, W., Zhang, J., Lu, C., Ding, Y., & Meng, Y. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01935-w · Cited by 15

GENE TARGET: A framework for evaluating Mendelian neurodevelopmental disorders for gene therapy

Chopra, M., Modi, M. E., Dies, K. A., Chamberlin, N. L., Buttermore, E. D., Brewster, S. J., Prock, L. A., & Şahin, M. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.08.007 · Cited by 16

Thalassemia and Nanotheragnostics: Advanced Approaches for Diagnosis and Treatment

Tariq, Z., Qadeer, M. I., Anjum, I., Hano, C., & Anjum, S. (2023) · Biosensors · doi:10.3390/bios13040450 · Cited by 14

Chitosan-Shelled Nanobubbles Irreversibly Encapsulate Morpholino Conjugate Antisense Oligonucleotides and Are Ineffective for Phosphorodiamidate Morpholino-Mediated Gene Silencing of DUX4

Falzarano, M. S., Argenziano, M., Marsollier, A.-C., Mariot, V., Rossi, D., Selvatici, R., Dumonceaux, J., Cavalli, R., & Ferlini, A. (2020) · Nucleic Acid Therapeutics · doi:10.1089/nat.2020.0862 · Cited by 14

Single-cell multiomic analysis identifies a HOX-PBX gene network regulating the survival of lymphangioleiomyomatosis cells

Olatoke, T., Wagner, A., Astrinidis, A., Zhang, E. Y., Guo, M., Zhang, A. G., Mattam, U., Kopras, E. J., Gupta, N., Smith, E. P., et al. (2023) · Science Advances · doi:10.1126/sciadv.adf8549 · Cited by 13

Precision medicine via the integration of phenotype-genotype information in neonatal genome project

Dong, X., Xiao, T., Chen, B., Lu, Y., & Zhou, W. (2022) · Fundamental Research · doi:10.1016/j.fmre.2022.07.003 · Cited by 14

Customer-centric product presentations for monoclonal antibodies

Bittner, B. (2023) · AAPS Open · doi:10.1186/s41120-022-00069-y · Cited by 12

RDKG-115: Assisting drug repurposing and discovery for rare diseases by trimodal knowledge graph embedding

Zhu, C., Xia, X., Li, N., Zhong, F., Yang, Z., & Liu, L. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107262 · Cited by 15

Pre-clinical development of AP4B1 gene replacement therapy for hereditary spastic paraplegia type 47

Wiseman, J. P., Scarrott, J. M., Alves-Cruzeiro, J., Saffari, A., Böger, C., Karyka, E., Dawes, E., Davies, A. K., Marchi, P. M., Graves, E. J., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00148-5 · Cited by 13

Strategies for Organ‐Targeted mRNA Delivery by Lipid Nanoparticles

Liao, H., Liao, J. P., Zeng, L., Cao, X., Fan, H., & Chen, J. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.2004 · Cited by 14

Genetics and therapy for pediatric eye diseases

Chen, H. Y., Lehmann, O. J., & Swaroop, A. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103360 · Cited by 16

The Magic of Proteases: From a Procoagulant and Anticoagulant Factor V to an Equitable Treatment of Its Inherited Deficiency

Pablo-Moreno, J. A. D., Miguel-Batuecas, A., de Sancha, M., & Liras, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076243 · Cited by 13

Application of implementation science framework to develop and adopt regulatory science in different national regulatory authorities

Shi, J., Chen, X., Hu, H., & Ung, C. O. L. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1172557 · Cited by 12

pH-Sensitive Polymer–Drug Conjugates

Gillies, E. R. (2024) · Chemistry of Materials · doi:10.1021/acs.chemmater.4c01700 · Cited by 13

Heparan Sulfate, Mucopolysaccharidosis IIIB and Sulfur Metabolism Disorders

Kaczor-Kamińska, M., Kamiński, K., & Wróbel, M. (2022) · Antioxidants · doi:10.3390/antiox11040678 · Cited by 12

Licensing of Orphan Medicinal Products—Use of Real-World Data and Other External Data on Efficacy Aspects in Marketing Authorization Applications Concluded at the European Medicines Agency Between 2019 and 2021

Naumann‐Winter, F., Wolter, F., Hermes, U., Malikova, E., Lilienthal, N., Meier, T., Kalland, M. E., & Magrelli, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.920336 · Cited by 12

Branched Antisense and siRNA Co‐Assembled Nanoplatform for Combined Gene Silencing and Tumor Therapy

Liu, J., Lu, X., Wu, T., Wu, X., Han, L., & Ding, B. (2020) · Angewandte Chemie · doi:10.1002/ange.202011174 · Cited by 12

Next-generation phenotyping integrated in a national framework for patients with ultra-rare disorders improves genetic diagnostics and yields new molecular findingsPreprint

Schmidt, A., Danyel, M., Grundmann, K., Brunet, T., Klinkhammer, H., Hsieh, T., Engels, H., Peters, S., Knaus, A., Moosa, S., et al. (2023) · medRxiv · doi:10.1101/2023.04.19.23288824 · Cited by 12

The Role of Long Noncoding RNA MALAT1 in Diabetic Polyneuropathy and the Impact of Its Silencing in the Dorsal Root Ganglion by a DNA/RNA Heteroduplex Oligonucleotide

Miyashita, A., Kobayashi, M., Ishibashi, S., Nagata, T., Chandrasekhar, A., Zochodne, D. W., & Yokota, T. (2022) · Diabetes · doi:10.2337/db21-0918 · Cited by 11

Cell-cell interaction in the pathogenesis of inherited retinal diseases

Du, X., Butler, A. G., & Chen, H. Y. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1332944 · Cited by 12

Tailored antisense oligonucleotides designed to correct aberrant splicing reveal actionable groups of mutations for rare genetic disorders

Wai, H. A., Svobodová, E., Herrera, N. R., Douglas, A. G. L., Holloway, J. W., Baralle, F. E., Baralle, M., & Baralle, D. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01292-1 · Cited by 11

Application progress of deep generative models in de novo drug design

Liu, Y., Xu, C., Yang, X., Zhang, Y., Chen, Y., & Liu, H. (2024) · Molecular Diversity · doi:10.1007/s11030-024-10942-5 · Cited by 14

Big data and transformative bioinformatics in genomic diagnostics and beyond

Saparov, A., & Zech, M. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.107311 · Cited by 11

Orphan drug development: The impact of regulatory and reimbursement frameworks

Huang, Y., Chao, W.-Y., Wang, C., & Chang, L. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.03.002 · Cited by 11

Recoding of Nonsense Mutation as a Pharmacological Strategy

Temaj, G., Telkoparan‐Akillilar, P., Nuhii, N., Chichiarelli, S., Saha, S., & Saso, L. (2023) · Biomedicines · doi:10.3390/biomedicines11030659 · Cited by 13

Coding Therapeutic Nucleic Acids from Recombinant Proteins to Next-Generation Vaccines: Current Uses, Limitations, and Future Horizons

Harisa, G. I., Faris, T. M., Sherif, A. Y., Alzhrani, R. F., Alanazi, S. A., Kohaf, N. A., & Alanazi, F. K. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00821-z · Cited by 11

Drug Development for Target Ribosomal Protein rpL35/uL29 for Repair of LAMB3R635X in Rare Skin Disease Epidermolysis Bullosa

Rathner, A., Rathner, P., Friedrich, A., Wießner, M., Kitzler, C. M., Schernthaner, J., Karl, T. R., Krauss, J. B., Lottspeich, F., Mewes, W., et al. (2021) · Skin Pharmacology and Physiology · doi:10.1159/000513260 · Cited by 13

Determining Commonalities in the Experiences of Patients with Rare Diseases: A Qualitative Analysis of US Food and Drug Administration Patient Engagement Sessions

Mease, C., Fermaglich, L. J., Jackler, K., Shermer, S., & Miller, K. L. (2023) · Patient · doi:10.1007/s40271-023-00648-5 · Cited by 10

Highly efficient capture approach for the identification of diverse inherited retinal disorders

Kao, H., Lin, T.-Y., Hsieh, F.-J., Chien, J.-Y., Yeh, E., Lin, W.-J., Chen, Y.-H., Ding, K.-H., Yang, Y., Chi, S.-C., et al. (2024) · npj Genomic Medicine · doi:10.1038/s41525-023-00388-3 · Cited by 10

Systematic and quantitative analysis of stop codon readthrough in Rett syndrome nonsense mutations

Lebeda, D., Fierenz, A., Werfel, L., Rosin‐Arbesfeld, R., Hofhuis, J., & Thoms, S. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02436-6 · Cited by 10

DNA nanotechnology-based strategies for minimising hybridisation-dependent off-target effects in oligonucleotide therapies

Li, X., Hu, H., Wang, H., Liu, J., Jiang, W., Zhou, F., & Zhang, J. (2024) · Materials Horizons · doi:10.1039/d4mh01158a · Cited by 12

Therapeutic potential of natural antisense transcripts and various mechanisms involved for clinical applications and disease prevention

Ali, A., Khatoon, A., Shao, C., Murtaza, B., Tanveer, Q., & Su, Z. (2023) · RNA Biology · doi:10.1080/15476286.2023.2293335 · Cited by 10

New orphan disease therapies from the proteome of industrial plasma processing waste- a treatment for aceruloplasminemia

Zanardi, A., Nardini, I., Raia, S., Conti, A., Ferrini, B., D’Adamo, P., Gilberti, E., Palma, G. D., Belloli, S., Monterisi, C., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-05820-7 · Cited by 9

Prospects and Ethics of ChatGPT in Biomedical Research and Medical Practice: An Emphasis on Nanotechnology

Faiyazuddin, M., Gholap, A. D., Maqsood, S., Abbas, S., Chaudhari, Y. S., Sharmila, S., & Webster, T. J. (2024) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2024.3925 · Cited by 10

Unlocking the Mysteries of Rare Disease Drug Development: A Beginner's Guide for Clinical Pharmacologists

AHMED, M. A., Abuasal, B., Barrett, J. S., Azer, K., Hon, Y. Y., Albusaysi, S., Shang, E. Y., Wang, M., Burian, M., & Rayad, N. (2025) · Clinical and Translational Science · doi:10.1111/cts.70215 · Cited by 9

Nanomaterial-enabled drug delivery systems for circadian medicine: bridging direct rhythm modulation and chronotherapy

Zeeshan, M., Hu, J., Mao, C., Danish, A., Xiong, Y., Irshad, M. S., Dao, V., & Liu, Z. (2025) · RSC Advances · doi:10.1039/d5ra04137f · Cited by 12

mRNA-Based Therapeutics: Advances in Drug Delivery, Comparative Innovations, and Biomedical Applications

Joshi, R., Sharma, S., Kapoor, D. U., Prajapati, B. G., Huanbutta, K., & Sriamornsak, P. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00774 · Cited by 10

Exploring the Contribution to ADHD of Genes Involved in Mendelian Disorders Presenting with Hyperactivity and/or Inattention

Fernàndez‐Castillo, N., Cabana‐Domínguez, J., Kappel, D. B., Torrico, B., Weber, H., Lesch, K., Lao, Ó., Reif, A., & Cormand, B. (2021) · Genes · doi:10.3390/genes13010093 · Cited by 9

Parental Guidance Suggested: Engaging Parents as Partners in Research Studies of Genomic Screening for a Pediatric Population

Powell, S. N., Byfield, G. E., Bennetone, A., Frantz, A. M., Harrison, L. K., James-Crook, E. R., Osborne, H., Owens, T. H., Shaw, J. L., O’Daniel, J. M., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.867030 · Cited by 11

Effective Newborn Screening for Type 1 and 3 Primary Hyperoxaluria

Höppe, B., Martín-Higueras, C., Borghese, L., Kaspar, S., Reusch, B., Beck, B. B., Walli, A., Janzen, E., Hegert, S., Janzen, N., et al. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.10.006 · Cited by 8

From roadmap to a sustainable end-to-end individualized therapy pathway

Jonker, A., Tataru, E., Dimmock, D., Bateman-House, A., Graessner, H., Baynam, G., Augustine, E., Jaffe, A., Pasmooij, A. M., Iliach, O., et al. (2025) · Therapeutic Advances in Rare Disease · doi:10.1177/26330040251339204 · Cited by 9

Identification of ER/SR resident proteins as biomarkers for ER/SR calcium depletion in skeletal muscle cells

Greer, L. K., Meilleur, K. G., Harvey, B. K., & Wires, E. S. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02368-9 · Cited by 8

Pharmacovigilance for rare diseases: a bibliometrics and knowledge-map analysis based on web of science

Xu, M., Li, G., Li, J., Xiong, H., & He, S. (2023) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-023-02915-y · Cited by 8

Newborn Screening and Long-term Outcomes

Powell, C. M. (2020) · PEDIATRICS · doi:10.1542/peds.2020-023663 · Cited by 8

Contributions from medical geneticists in clinical trials of genetic therapies: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG)

Peña, L. D. M., Burrage, L. C., Enns, G. M., Esplin, E. D., Harding, C. O., Mendell, J. R., Niu, Z., Scharfe, C., Yu, T. W., & Koeberl, D. D. (2023) · Genetics in Medicine · doi:10.1016/j.gim.2023.100831 · Cited by 8

The IRDiRC Chrysalis Task Force: making rare disease research attractive to companies

Beaverson, K. L., Julkowska, D., Letinturier, M. C. V., Aartsma-Rus, A. M., Austin, J., Bueren, J. A., Frost, S., Hamamura, M., Larkindale, J., LaRosa, G., et al. (2023) · Therapeutic Advances in Rare Disease · doi:10.1177/26330040231188979 · Cited by 8

A drug discovery toolbox for Nuclear Magnetic Resonance (NMR) characterization of ligands and their targets

LeBlanc, R. M., & Mesleh, M. F. (2020) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2020.11.008 · Cited by 8

Enantiomeric Resolution and Absolute Configuration of a Chiral δ-Lactam, Useful Intermediate for the Synthesis of Bioactive Compounds

Listro, R., Rossino, G., Volpe, S. D., Stabile, R., Boiocchi, M., Malavasi, L., Rossi, D., & Collina, S. (2020) · Molecules · doi:10.3390/molecules25246023 · Cited by 8

Cas-Based Systems for RNA Editing in Gene Therapy of Monogenic Diseases: In Vitro and in Vivo Application and Translational Potential

Reshetnikov, V. V., Chirinskaite, A. V., Sopova, J. V., Ivanov, R. A., & Леонова, Е. И. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.903812 · Cited by 8

En Route to Targeted Ribosome Editing to Replenish Skin Anchor Protein LAMB3 in Junctional Epidermolysis Bullosa

Wimmer, B., Friedrich, A., Poeltner, K., Edobor, G., Moßhammer, C., Temaj, G., Rathner, A., Karl, T. R., Krauss, J. B., von Hagen, J., et al. (2023) · JID Innovations · doi:10.1016/j.xjidi.2023.100240 · Cited by 10

Improvement in Tol2 transposon for efficient large-cargo capacity transgene applications in cultured cells and zebrafish (Danio rerio)

Wang, P., 1上海交通大学医学院新华医院儿科心内科, 上. 2., Deng, H., Xu, R., Du, J., & Tao, R. (2024) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2024.026 · Cited by 7

Plant molecular farming: a promising frontier for orphan drug production

Shanmugaraj, B., Ravi, K., & Baladevan, K. (2025) · Biotechnology Letters · doi:10.1007/s10529-025-03596-2 · Cited by 7

Spectrum and epidemiology of rare diseases in a Chinese natural population of 14.31 million residents, 2012–2023

Li, M., Li, Q., Zhao, M., Kim, H., Feng, R.-Q., Guo, M., heng, J.-P., Yang, J., & Liu, C. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03933-8 · Cited by 7

Clinical utility and cost-effectiveness of BeginNGS newborn screening by genome sequencing and standard newborn screening for severe childhood genetic diseases: an adaptive, international and comparative clinical trial

Reimers, R., Bailey, M., Brown, C., Chan, K., Defay, T. R., Finkel, T. H., Kahn, S. D., Protopsaltis, L., Stoddard, L., Talati, A. J., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-098609 · Cited by 10

Protein Transduction Domain-Mediated Delivery of Recombinant Proteins and In Vitro Transcribed mRNAs for Protein Replacement Therapy of Human Severe Genetic Mitochondrial Disorders: The Case of Sco2 Deficiency

Miliotou, Α. N., Foltopoulou, P. F., Ingendoh‐Tsakmakidis, A., Tsiftsoglou, A. S., Vizirianakis, I. S., Pappas, I. S., & Papadopoulou, L. C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010286 · Cited by 7

Human-based complex in vitro models: their promise and potential for rare disease therapeutics

Parvatam, S., Pistollato, F., Marshall, L. J., Furtmann, F., Jahagirdar, D., Choudhury, M. C., Mohanty, S., Mittal, H., Meganathan, S., & Mishra, R. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1526306 · Cited by 7

The role of serum amyloid A1 in the adipogenic differentiation of human adipose-derived stem cells basing on single-cell RNA sequencing analysis

Qu, R., He, K., Yang, Y., Fan, T., Sun, B., Khan, A. U., Huang, W., Ouyang, J., Pan, X., & Dai, J. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02873-5 · Cited by 8

Real-world use of orphan medicinal products (OMPs) in rare disease (RD) patients: A population-based registry study

Mazzucato, M., Minichiello, C., Vianello, A., Pozza, L. V. D., Toto, E., & Facchin, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.940010 · Cited by 7

A comprehensive review on the current status of CRISPR based clinical trials for rare diseases

Badwal, A. K., & Singh, S. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134097 · Cited by 10

Trend of clinical trials of new drugs for rare diseases in China in recent 10 years

Peng, A., Fan, X., Zou, L., Chen, H., & Xiang, J. (2023) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-023-02713-6 · Cited by 6

Hydrogels: current biomedical applications and future directions

Wu, H., Piao, G., Chen, Q., Luo, W., Liu, J., Lan, Y., Wang, Y., Zhou, J., Yang, K., Xiao, J., et al. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00525-1 · Cited by 7

A mouse model of Zhu-Tokita-Takenouchi-Kim syndrome reveals indispensable SON functions in organ development and hematopoiesis

Vukadin, L., Park, B., Mohamed, M., Li, H., Elkholy, A., Torrelli-Diljohn, A., Kim, J., Jeong, K., Murphy, J. M., Harvey, C. A., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.175053 · Cited by 6

Evolving Research and Development Landscape for Rare Diseases: Growing Concerns Over Orphan Drug Lag in Japan

Enya, K., Kageyama, I., Kobayashi, Y., Lim, Y., Sengoku, S., & Kodama, K. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3553 · Cited by 6

Assessing Post‐Marketing Requirements for Orphan Drugs: A Cross‐Sectional Analysis of FDA and EMA Oversight

Yu, J. H., Lee, S., Kim, Y. J., Kim, W., Lee, M. J., & Kim, Y. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3397 · Cited by 6

An EU task force to assess the burden of rare diseases

Kolkhir, P., Grad, D. A., Charalampous, P., Oliveira, C. C., Mechili, E. A., Unim, B., Pearce, D. A., Maurer, M., Devleesschauwer, B., & Haagsma, J. A. (2023) · Nature Medicine · doi:10.1038/s41591-023-02207-9 · Cited by 6

Health-related quality of life in patients with diverse rare diseases: An online survey

Rao, A., Yabumoto, M., Ward-Lev, E., Miller, E. G., Naik, H., & Halley, M. C. (2024) · Genetics in Medicine Open · doi:10.1016/j.gimo.2024.101889 · Cited by 5

EMA approved orphan medicines since the implementation of the orphan legislation

Hahl, E., Kurko, T., Koskinen, H., Airaksinen, M., & Sarnola, K. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03756-7 · Cited by 5

Therapeutics in Metabolic Diseases

Natesan, V. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-5642-3_17 · Cited by 5

Rare diseases and pyruvate kinase M2: a promising therapeutic connection

Kapoor, S., Kalmegh, V., Kumar, H., Mandoli, A., & Shard, A. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103949 · Cited by 5

Functional prediction of the potential NGLY1 mutations associated with rare disease CDG

Yuan, S., Chen, Y., Zou, L., Lu, X., Liu, R., Zhang, S., Zhang, Y., Chen, C., Cheng, D., Chen, L., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28787 · Cited by 5

Clinical trial evidence supporting FDA approval of novel orphan drugs between 2017 and 2023

Chen, Q., Xu, Y., Qu, R., Luo, X., & Yue, Y. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104102 · Cited by 5

Drug–device combinations in rare diseases: Challenges and opportunities

Tãtaru, E.-A., Dooms, M. M., Gonzaga-Jauregui, C. G., Pasmooij, A. M. G., O’Connor, D. J., & Jonker, A. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104343 · Cited by 5

Context-Sensitive Common Data Models for Genetic Rare Diseases – A Concept

Ahmadi, N., Zoch, M., Sedlmayr, B., Schuler, K., Hahn, W., Sedlmayr, M., & Wolfien, M. (2023) · Studies in health technology and informatics · doi:10.3233/shti230443 · Cited by 5

Actin Cytoskeleton Polymerization and Focal Adhesion as Important Factors in the Pathomechanism and Potential Targets of Mucopolysaccharidosis Treatment

Gaffke, L., Rintz, E., Pierzynowska, K., & Węgrzyn, G. (2023) · Cells · doi:10.3390/cells12131782 · Cited by 5

2017-2023: state of the art of gene therapies in rare diseases in Europe: the dynamics of clinical R&D, new approved treatments and expected therapies in the pipelines

Gicquel, T., Cortial, L., Lutsyk, K., Forget, S., Braun, S., Boyer, P.-O., Laugel, V., & Blin, O. J. (2023) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2023.29 · Cited by 5

Together for the greater goods: legitimising social innovation in the pharmaceutical field

Kleinhout‐Vliek, T., Boon, W., Hagendijk, R., Hoekman, J., & Moors, E. H. M. (2024) · Innovation The European Journal of Social Science Research · doi:10.1080/13511610.2024.2305908 · Cited by 5

How to develop new systemic treatments in ultra-rare cancers with high unmet needs? The case of alveolar soft-part sarcoma

Stacchiotti, S., Bouche, G., Herold, R., Pantziarka, P., Schuster, K., Wilson, R., Pignatti, F., & Kasper, B. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114003 · Cited by 5

Challenges and Future Opportunities in Rare Genetic Disorders: A Comprehensive Review

Madhu, N. R., Biswas, G., Paul, S., Adhikari, S., Sarkar, B., Rafeeq, M. M., & Umair, M. (2024) · Springer eBooks · doi:10.1007/978-981-99-9323-9_9 · Cited by 8

Fair Funding Decisions: Consistency of the Time Horizons Used in the Calculation of Quality-Adjusted Life Years for Therapies for Very Rare Diseases by the National Institute for Health and Care Excellence in England

Barman‐Aksözen, J., Hentschel, N., Pettersson, M., Schupp, E., Granata, F., Dechant, C., Aksözen, M. H., & Falchetto, R. A. (2024) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph21050616 · Cited by 4

Regulation of Precise DNA Repair by Nuclear Actin Polymerization: A Chance for Improving Gene Therapy?

He, X., & Brakebusch, C. (2024) · Cells · doi:10.3390/cells13131093 · Cited by 5

Implementing genomic medicine in clinical practice for adults with undiagnosed rare diseases

Ahn, J. H., Yoon, J. G., Cho, J., Lee, S., Kim, M. J., Kim, M. J., Kim, S. Y., Lee, S., Chu, K., Lee, S. K., et al. (2024) · npj Genomic Medicine · doi:10.1038/s41525-024-00449-1 · Cited by 5

Ecosystem Barriers to Innovation Adoption in Clinical Practice

MacRae, C. A., Deo, R. C., & Shaw, S. Y. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.11.007 · Cited by 5

Enzyme Replacement Therapy & Other Therapeutic Frontiers in Infantile Metabolic Disorders

Choi, H., Sriram, A., Sargiotto, C., & Fajardo, V. M. (2025) · NeoReviews · doi:10.1542/neo.26-12-081 · Cited by 4

Non-oncology orphan drug development: Productivity and probability of success

Parker, S., Hajjar, J. E., Jonker, A. H., Kahn, S. R., Kritikou, P., Kyriakopoulou, C., & Haight, A. R. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104568 · Cited by 4

Innovative lipid nanoparticle formulations: Bridging the gap toward decentralized personalized gene therapies

Streiber, M., Schubert, U. S., & Traeger, A. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115023 · Cited by 7

A Patient-Centric, Coordinated Care Model for Rare Diseases: The Multidisciplinary Consultation Program at Peking Union Medical College Hospital

Xie, J., Jin, Y., Shen, M., Chen, L., & Zhang, S. (2023) · NEJM Catalyst · doi:10.1056/cat.23.0297 · Cited by 4

Lactic acid bacteria as microbial cell factories for the in vivo delivery of therapeutic proteins as secretable TAT fusion products

Medici, G., Candini, G., Mottolese, N., Uguagliati, B., Trebbi, F., Loi, M., Bove, A. M., Stojanov, S., Esposito, E., Vitagliano, R., et al. (2025) · Journal of Biological Engineering · doi:10.1186/s13036-025-00538-4 · Cited by 4

Tecnologias para COVID-19 e terapias inovadoras: desafios contemporâneos

Leineweber, F. V., & Bermudez, J. A. Z. (2021) · Cadernos de Saúde Pública · doi:10.1590/0102-311x00158121 · Cited by 5

Development of orphan drugs for rare diseases

Yoo, H. (2023) · Korean Journal of Pediatrics · doi:10.3345/cep.2023.00535 · Cited by 38

Research advances in treatment methods and drug development for rare diseases

Han, Q., Fu, H., Chu, X., Wen, R., Zhang, M., You, T., Fu, P., Qin, J. G., & Cui, T. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.971541 · Cited by 28

Targeted Therapeutics for Rare Disorders

Keeling, K. M., Leier, A., Bedwell, D. M., Chen, A. T., Kesterson, R. A., Marquez‐Lago, T. T., Müller, U. F., Zhou, J., Popplewell, L. J., & WALLIS, D. E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00009-5 · Cited by 1

Protein replacement therapies for rare diseases: a breeze for regulatory approval?

Gorzelany, J. A., & de Souza, M. P. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005007 · Cited by 33

Evolution of therapy monogenic orphan diseases and regulatory aspects of orphan medicinal products development

Poteryaev, D. A., & Khamitov, R. (2026) · Biological Products. Prevention, Diagnosis, Treatment · doi:10.30895/2221-996x-2026-26-2-127-143